Literature DB >> 20602543

Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.

Xin An1, Pei-Rong Ding, Yu-Hong Li, Feng-Hua Wang, Yan-Xia Shi, Zhi-Qiang Wang, You-Jian He, Rui-Hua Xu, Wen-Qi Jiang.   

Abstract

BACKGROUND: Elevated neutrophil to lymphocyte ratio (NLR) is linked with worse survival in many malignancies, whereas its association with pancreatic cancer (PC) remains unclear.
METHODS: We retrospectively reviewed 95 patients with locally advanced or metastatic PC receiving gemcitabine-based chemotherapy. The prognostic value of NLR was evaluated.
RESULTS: Elevated pretreatment NLR (> 5) was observed in 16 out of 89 eligible patients, which was identified as an independent prognostic factor for overall survival (OS). The median OS for patients with elevated and normal NLR were 2.4 months and 7.7 months, respectively (p < 0.001).
CONCLUSIONS: Elevated NLR is a predictor of shorter survival in patients with advanced PC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602543     DOI: 10.3109/1354750X.2010.491557

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  97 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients.

Authors:  Sabine Krenn-Pilko; Uwe Langsenlehner; Tatjana Stojakovic; Martin Pichler; Armin Gerger; Karin S Kapp; Tanja Langsenlehner
Journal:  Tumour Biol       Date:  2015-07-29

3.  Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.

Authors:  Yue-Can Zeng; Feng Chi; Rui Xing; Ming Xue; Li-Na Wu; Mei-Yue Tang; Rong Wu
Journal:  Jpn J Clin Oncol       Date:  2015-11-25       Impact factor: 3.019

4.  Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy.

Authors:  Shun-Jun Fu; Shun-Li Shen; Shao-Qiang Li; Yun-Peng Hua; Wen-Jie Hu; Li-Jian Liang; Bao-Gang Peng
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

5.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

6.  The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.

Authors:  Daniel Keizman; Maya Ish-Shalom; Peng Huang; Mario A Eisenberger; Roberto Pili; Hans Hammers; Michael A Carducci
Journal:  Eur J Cancer       Date:  2011-10-19       Impact factor: 9.162

7.  Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.

Authors:  Ahmet Taner Sümbül; Ahmet Sezer; Hüseyin Abalı; Fatih Köse; Ilhami Gültepe; Hüseyin Mertsoylu; Sadık Muallaoğlu; Özgür Özyılkan
Journal:  Int Urol Nephrol       Date:  2014-02-13       Impact factor: 2.370

8.  Prognostic Significance of the Immunological Indices in Patients Who Underwent Complete Resection of Pulmonary Metastases of Colorectal Cancer.

Authors:  Yuki Okazaki; Masatsune Shibutani; E N Wang; Hisashi Nagahara; Tatsunari Fukuoka; Yasuhito Iseki; Shinichiro Kashiwagi; Hiroaki Tanaka; Kiyoshi Maeda; Kosei Hirakawa; Masaichi Ohira
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

9.  Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma.

Authors:  Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Yukio Yoshida; Masaki Tanaka; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

10.  FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.

Authors:  E Bonnet; C Mastier; A Lardy-Cléaud; P Rochefort; M Sarabi; P Guibert; A Cattey-Javouhey; F Desseigne; C de La Fouchardière
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.